Fertility: There are no data in humans to evaluate the effect of topical corticosteroids on fertility (see Pharmacology: Toxicology: Pre-Clinical Safety Data under Actions).
Pregnancy: There are limited data from the use of fluticasone propionate in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see Pharmacology: Toxicology: Pre-Clinical Safety Data under Actions). The relevance of this finding to humans has not been established; however, administration of CUTIVATE Cream during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus. The minimum quantity should be used for the minimum duration.
Lactation: The safe use of topical corticosteroids during lactation has not been established.
It is not known whether the topical administration of corticosteroids could result in sufficient systemic absorption to product detectable amounts in breast milk.
When measurable plasma levels were obtained in lactating laboratory rats following subcutaneous administration, there was evidence of fluticasone propionate in the milk.
Administration of CUTIVATE Cream during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.
If used during lactation, CUTIVATE Cream should not be applied to the breasts to avoid accidental ingestion by the infant.